Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285785 · ClinicalTrials.gov registry record · Phase 4
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
A Phase 4 study of Diarrhea and Bacterial Infection, sponsored by Bausch Health Americas.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
- 5
- Study locations
NCT07285785: Recruiting Phase 4 study of Diarrhea and Bacterial Infection, sponsored by Bausch Health Americas.
NCT07285785 is a Phase 4 study of Diarrhea and Bacterial Infection that is actively recruiting participants, run by Bausch Health Americas. The registered enrollment target is 54 participants, below the 155-participant average among 24 other Diarrhea trials with a reported enrollment target (65% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07285785, a Phase 4 study of Diarrhea and Bacterial Infection, is actively recruiting participants, sponsored by Bausch Health Americas.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (ORT) compared with ORT alone. The main questions it aims to answer are: How does rifaximin 200 mg move through and leave the body in children with acute diarrhea? Is rifaximin safe for children in this age group? Does rifaximin plus ORT help resolve diarrhea faster than ORT alone? Researchers will compare rifaximin plus ORT to ORT alone to see if adding rifaximin improves outcomes. Participants will: Take one rifaximin 200 mg tablet + ORT three times a day for 3 days or receive ORT alone Receive oral rehydration therapy according to the investigator's standard of care Attend up to 4 clinic visits over 5 days and receive 4 follow-up phone calls Provide blood samples on Day 1 and Day 3 for pharmacokinetic testing (rifaximin group only) Provide stool samples to identify bacterial pathogens Keep a diary of stool frequency and consistency to help determine when diarrhea resolves Be monitored for side effects, vital signs, and laboratory changes
Primary Outcome
Cmax levels following rifaximin 200 mg + ORT
Conditions Studied
Interventions
- DRUG Rifaximin 200 mg Tablet
- OTHER Oral Rehydration Therapy (ORT)
Study Locations (5)
Florida
- Direct Helpers - Hialeah
- SouthCoast Research Center - Miami
- Oceane7 Medical & Research Center, Inc - Miami
Texas
- LinQ Research - Rosharon
Virginia
- Tekton Research - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2026-02-11 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 4 |
What NCT07285785 shows while recruiting
NCT07285785 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 155-participant average among 24 other Diarrhea trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Diarrhea appearing as the primary indexed condition, and to 2 interventions - of which Rifaximin 200 mg Tablet is the first listed.
NCT07285785 lists 5 locations in 3 states (Florida, Texas, Virginia).
Frequently Asked Questions
What is clinical trial NCT07285785 about?
NCT07285785 is a clinical study titled "Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea". The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (...
What is the current status of trial NCT07285785?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2026-02-11. Estimated completion is 2027-07-31.
What conditions does trial NCT07285785 study?
This clinical trial studies the following conditions: Diarrhea, Bacterial Infection, Gastroenteritis.
What interventions are being tested in trial NCT07285785?
The interventions under investigation include: Rifaximin 200 mg Tablet (DRUG), Oral Rehydration Therapy (ORT) (OTHER).
Who is sponsoring clinical trial NCT07285785?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07285785 being conducted?
This trial has 5 study locations across Florida, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07285785's enrollment target sits among peer trials
54 13th of 24 higher than 12 of 24 other Diarrhea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diarrhea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Examining the Effect of Ondansetron on Bowel Prep Success
COMPLETED · Phase 4
-
GI Alpha-Gal Study
RECRUITING · NA
-
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
RECRUITING · Phase 1
-
Fecal Microbiota Transplantation for IBS
RECRUITING · Phase 2
-
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
RECRUITING · Phase 1
-
Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI